Quick Answer
Avalo Therapeutics, Inc. reported Net Income Loss of -$78.26 million for the year ending 2025.
- Avalo Therapeutics, Inc. showed a decrease of -122.8% in Net Income Loss from 2024 to 2025.
- This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Avalo Therapeutics, Inc.'s Net Income Loss has declined by 499.9%.
- Historical annual values: Fiscal year 2025: -$78.26 million | Fiscal year 2024: -$35.13 million | Fiscal year 2023: -$31.54 million | Fiscal year 2022: -$41.66 million | Fiscal year 2021: -$84.38 million | Fiscal year 2020: -$63.50 million | Fiscal year 2019: -$16.07 million | Fiscal year 2018: -$40.05 million | Fiscal year 2017: $11.87 million | Fiscal year 2016: -$16.47 million | Fiscal year 2015: -$10.49 million | Fiscal year 2014: -$16.06 million | Fiscal year 2013: -$13.05 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: